Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

pharmaphorum

JANUARY 29, 2021

This has, of course, garnered immense excitement – Doctors Emmanuelle Charpentier and Jennifer Doudna were named winners of the Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology. Zinc fingers. Macrae had previously worked at GSK and Takeda before he was recruited by Sangamo.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

World of DTC Marketing

JANUARY 31, 2021

Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases. Still, she is missing a lot of facts at a time when hospital and health insurance costs are soaring. In pharma R&D returns have declined to 1.8

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

pharmaphorum

OCTOBER 6, 2022

By reducing the disease to its key components, a computer-readable network of disease markers was characterised using genetic, biomarker, and clinical data; the model was also populated with ‘disease vs control’ data. Disease modelling Gulf War Illness. Tinker, tailor, soldier, therapy.

In-Vivo 98

In-Vivo Research Genetics Drugs 98

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

NOVEMBER 17, 2020

Dr. Anderson has been an early adopter in blastocyst embryo transfer, cryopreservation and pioneered blastocyst biopsy with and without laser technology for genetic testing. Tony completed his doctoral studies at a Nova Southeastern University , a private university in South Florida. . SARASOTA, Fla. ,

In-Vivo 52

In-Vivo In-Vitro Genetics Doctor 52